SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Torben Noerup Nielsen who wrote (29967)1/8/2000 3:14:00 PM
From: Henry Niman  Respond to of 32384
 
Torben, Plaque psoriasis is a MAJOR consideration. I think that many MDs know that there is an association between the treatment of CTCL and psoriasis. If a drug works for one condition, it frequently works for the other. Targretin will be available in 75 mg tablets and I think that the 300 mg/m2 translates into something like 500 mg for an person of average build and weight, so psoriasis patients can easily start at a lower dose.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News